

**BioPorto A/S | Annual General Meeting | Candidates for the Board of Directors**  
(Updated on 8 April 2021)

**Thomas Magnussen (born 1953, Danish)**

Thomas Magnussen has been a member of the Board of Directors of the Company since 2013 and is Chairman of the Board of Directors. Thomas Magnussen is Chief Executive Officer of Therazone ApS and Thera Property ApS. Thomas Magnussen is a serial entrepreneur within high-tech, focusing on start-up companies with global business potential. Thomas Magnussen has experience in commercialization strategies within nanotechnology, ICT and MedTech industries and has previously been Chairman of the Board of Directors of QuantumWise ApS and Zylinec A/S. Thomas Magnussen holds an MBA from INSEAD as well as a Ph.D. and MSc from the Technical University of Denmark.

**Christopher Lindop (born 1957, American)**

Christopher James Lindop has been a member of the Board of Directors of the Company since 2019. Christopher James Lindop qualified as a chartered accountant and certified public accountant and was previously a partner with Arthur Andersen LLP and Ernst & Young LLP. In 2003, Christopher James Lindop took the position as Chief Financial Officer of Inverness Medical Ltd., before he became Chief Financial Officer and EVP Business Development at Haemonetics Corporation Ltd. (HAE) in 2007. Since 2017, Christopher James Lindop has been Chief Financial Officer of Quotient Limited (QTNT) until his retirement in May 2020. From 2007 until 2018 Christopher James Lindop was a member of the Board of Directors of Parexel International (PRXL) where he served as chairman of the audit committee and member of the nominating and governance Committee. Christopher James Lindop has considerable experience in management of US listed health care and diagnostic companies and within finance and reporting, corporate governance, mergers & acquisitions, funding and strategy development and execution.

**Michael S. Singer (born 1973, American)**

Michael Singer has been a member of the Board of Directors of the Company since 2019. Michael Scott Singer has served since 2016 as Chief Scientific Officer and co-founder of Cartesian Therapeutics, Inc., a U.S. clinical-stage cell and gene therapy company. Prior to this, he was co-founder and Chief Scientific Officer of Topokine Therapeutics, Inc., where he was responsible for pre-clinical and clinical development of the Company's adipomodulatory products. Topokine Therapeutics, Inc. was acquired by Allergan in 2016. Michael Scott Singer was also co-founder and Chief Scientific Officer of HealthHonors Corporation, acquired by Healthways in 2009. He also served as Director of Translational Medicine at Novartis and a physician at Harvard and the U.S. Veterans Affairs Medical Center. Michael Scott Singer serves on the clinical faculty and as an entrepreneur in residence at Yale University. He volunteers on the Board of Museum Advisors at the Museum of Science, Boston. He holds an M.D. cum laude and a Ph.D. in neuroscience from Yale University, CT.

**Don M. Hardison (born 1950, American)**

Don Hardison most recently served as the President, Chief Executive Officer and as a member of the Board of Directors of Biotheranostics, Inc., an oncology-focused molecular diagnostics company which was acquired in February 2021 by Hologic Inc. Prior to Biotheranostics, he was the President and Chief Executive Officer of Good Start Genetics, a molecular diagnostics company focused on reproductive health. Earlier in his career, he held a number of executive and senior management positions at a number of public companies, including: Laboratory Corporation of America and Quest Diagnostics, the two largest US clinical laboratory companies; Exact Sciences Corporation, a molecular diagnostics company; and SmithKline Beecham Corporation, a pharmaceutical company. He currently serves on the Board of Directors of several privately held companies, including Stemina Biomarker Discovery Inc., Seventh Sense Biosystems, and IQuity, Inc. He also served on the board of directors of Exact Sciences Corporation from May 2000, through its initial public offering in February 2001, until August 2007. Don Hardison received his Bachelor of Arts degree (political science) from the University of North Carolina, Chapel Hill.

**John McDonough (born 1959, American)**

John McDonough currently serves as Chairman of the Board of Directors and previously served as President and Chief Executive Officer of T2 BioSystems, Inc., a diagnostics company focused on the rapid detection of sepsis-causing pathogens. From 2003 to 2007, John held a number of positions at Cytyc Corporation, a company focused on women's health, and ultimately served as President at Cytyc Development Corporation. He had the responsibility of designing and executing Cytyc Corporation's growth strategy for expanding the company from a single product company with revenue of approximately \$300 million to a diverse women's health company with revenue of approximately \$750 million and led the efforts that resulted in Cytyc's acquisition by Hologic, Inc. in October 2007, for over \$6 billion. John McDonough is currently a member of the Board of Directors at Solace Therapeutics and Cytrellis Biosystems. He earned his undergraduate degree in Business from Stonehill College.

All the above candidates are considered independent according to the Danish Corporate Governance Recommendations.

**Jan Leth Christensen (born 1963, Danish)**

Jan Leth Christensen, attorney-at-law, is currently a board member and partner at Lønberg & Leth Christensen Advokataktieselskab. Jan Leth Christensen is chairman of Havnens Bygningsudlejnings A/S, Best Ejendomme A/S and Advokaternes Ejendomsadministration A/S and serves as a member of the executive management and/or the board of directors of several other companies and foundations. Jan Leth Christensen holds a master's degree in law from the University of Copenhagen.

Jan Leth Christensen controls Ejendomsselskabet Jano ApS, which according to major shareholder notifications controls more than 10% of the shares of BioPorto A/S. He is considered independent in accordance with the criteria laid down in the Danish Recommendations on Corporate Governance.

Additional board and management positions:

Board member

WRP-Holding A/S  
Esplanaden Berlin Holding A/S  
Lønberg & Leth Christensen Advokataktieselskab  
Ner-Finans Aps  
Havnens Bygningsudlejning A/S  
Ejendomsselskabet Jano Aps  
Best Ejendomme A/S  
Advokaternes Ejendomsadministration A/S  
K/S Hørsvinget 4  
Hyldegårdsvej 40 A/S  
Havnen Lersø Parkallé 107 Aps  
W. Lynggaard Petersen Holding A/S  
Søborgstræde 2 A/S

Executive manager

Lønberg & Leth Christensen Advokataktieselskab  
E.G. Kapital Aps  
Jano Div Aps  
Ejendomsselskabet Jano Aps  
Leth Christensen Advokatanpartsselskab Holding  
Erokito Aps  
Residuum Aps  
Nordre Kystvej 30-32 Aps  
Nordre Kystvej Holding Aps  
Store Torv 12 Aps  
Jlc E.G. Kapital Holding Aps  
Ogov 50 Holding Aps  
Ogov 50 Aps  
Jano Vent Aps  
Toldbodgade 36 A-B Aps  
Wildersgade 44 Kbh Aps  
E.G. Frederikssundsvej ApS